Gene therapy and reproductive medicine

Fertility and Sterility

Volumn 77, Issue 4, 2002, Pages 645-657

  Stribley, John M ^a,b,c   Rehman, Khurram S ^b   Niu, Hairong ^d   Christman, Gregory M ^a,b  

^a Reproductive Sciences Program   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

^c The Center for Human Gene Therapy   (United States)

^d PFIZER INC   (United States)

Author keywords

Fetal therapy; Gene therapy; Leiomyoma; Ovarian carcinoma

Indexed keywords

ACICLOVIR; ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; CARBOPLATIN; CISPLATIN; CYTOKINE RECEPTOR; CYTOSINE DEAMINASE; DNA VACCINE; GANCICLOVIR; INTERLEUKIN 2; LENTIVIRUS VECTOR; LIPOSOME; ORNITHINE OXOACID AMINOTRANSFERASE; PACLITAXEL; PROTEIN P53; RECOMBINANT DNA; RETROVIRUS VECTOR; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS NUCLEOPROTEIN; VIRUS RNA;

ADENO ASSOCIATED VIRUS; ARTICLE; ARTIFICIAL CHROMOSOME; CANCER IMMUNOTHERAPY; CELL TRANSFER; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONGENITAL DISORDER; CYSTIC FIBROSIS; DNA DRUG COMPLEX; DNA TRANSFER; DNA VECTOR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GENE THERAPY; GERM LINE; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; MEDICAL ETHICS; MESOTHELIOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SQUAMOUS CELL CARCINOMA; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; FEMALE; FEMALE GENITAL TRACT TUMOR; FETUS DISEASE; GENE VECTOR; GENETICS; GYNECOLOGIC DISEASE; METHODOLOGY; PREGNANCY; REPRODUCTION; RETROVIRUS; REVIEW;

ADENOVIRIDAE; DNA, RECOMBINANT; FEMALE; FETAL DISEASES; GENE THERAPY; GENETIC VECTORS; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PREGNANCY; REPRODUCTION; RETROVIRIDAE;

EID: 0036009789     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)03233-2     Document Type: Review

References (64)

1. Gene therapy and ovarian cancer: A review
2. Transfer of genes to humans: Early lessons and obstacles to success
3. The Human Genome Project: Implications for the practicing obstetrician
4. Nonviral gene therapy: The promise of genes as pharmaceutical products
5. Gene therapy - Promise, pitfalls, and prognosis
6. Genetic therapy. Past, present, and future
7. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
8. Prenatal application of somatic gene therapy
9. A randomized trial of prenatal ultrasonographic screening: Impact on the detection, management, and outcome of anomalous fetuses
10. Rival genome sequencers celebrate a milestone together
11. The basic science of gene therapy
12. Methods of gene delivery
13. Development of optimized vectors for gene therapy
14. Gene therapy. Is the future here yet?
15. Gene transfer technologies for the gene therapy of cancer
16. Gene transfer and gene therapy: Principles, prospects and perspective
17. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes
18. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy
19. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
20. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells
21. Towards gene therapy for the central nervous system
22. Basic strategies for gene therapy: Gene replacement
23. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function
24. Gene therapy in transplantation
25. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
26. Lentiviral vectors: Aids for gene therapy
27. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
28. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1
29. Development of HIV vectors for anti-HIV gene therapy
30. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
31. A packaging cell line for lentivirus vectors
32. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
33. Expanded-capacity adenoviral vectors - The helper-dependent vectors
34. Adenovirus and adeno-associated virus mediated gene transfer
35. Heterologous protection against influenza by injection of DNA encoding a viral protein
36. Generation of transgenic mice and germline transmission of a mammalian artificial chromosome introduced into embryos by pronuclear microinjection
37. Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues
38. Micromanipulation of gametes and pre-implantation mammalian embryos - A review
39. Report of the FIGO Committee for the study of ethical aspects of human reproduction
40. In utero gene therapy: One step closer to reality
41. Prospects for in utero human gene therapy
42. Feasibility of hepatocellular transplantation via the umbilical vein in prenatal and perinatal lambs
43. Transduction of human trophoblast cells by recombinant adenoviruses is differentiation dependent
44. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter
45. Human papillomaviruses: Their clinical significance in the management of cervical carcinoma
46. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16
47. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells
48. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human cervical cancers
49. Molecular aspects of breast and ovarian cancer
50. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals
51. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
52. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma
53. Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model
54. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: A specific gene therapy strategy
55. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer
56. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance
57. Somatic gene therapy for cancer: The utility of transferrinfection in generating "tumor vaccines."
58. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
59. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase
60. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: Potential application of gene therapy to endometrial cancer
61. Medical ethics. Principles for human gene therapy studies